Immuneering Corporation

NasdaqGM:IMRX Stock Report

Market Cap: US$439.7m

Immuneering Management

Management criteria checks 3/4

Immuneering's CEO is Ben Zeskind, appointed in Feb 2008, has a tenure of 17.83 years. total yearly compensation is $1.95M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 4.97% of the company’s shares, worth $21.84M. The average tenure of the management team and the board of directors is 4.3 years and 3.9 years respectively.

Key information

Ben Zeskind

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage31.71%
CEO tenure17.8yrs
CEO ownership5.0%
Management average tenure4.3yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth

Nov 22
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth

Immuneering Corporation: Ripping On A Questionable Catalyst

Aug 26

Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely

Jul 01
Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely

Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely

Mar 18
Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Aug 30
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

May 13
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Immuneering wins FDA nod to study lead asset in solid tumors

Sep 30

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Sep 02

Immuneering initiated a Buy by Chardan, PT set to $18

Jul 08

CEO Compensation Analysis

How has Ben Zeskind's remuneration changed compared to Immuneering's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$62m

Jun 30 2025n/an/a

-US$62m

Mar 31 2025n/an/a

-US$62m

Dec 31 2024US$2mUS$617k

-US$61m

Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$2mUS$593k

-US$53m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$2mUS$570k

-US$51m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$2mUS$400k

-US$34m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$806kUS$293k

-US$17m

Compensation vs Market: Ben's total compensation ($USD1.95M) is about average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.

CEO

Ben Zeskind (43 yo)

17.8yrs
Tenure
US$1,945,092
Compensation

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Zeskind
Co-Founder17.8yrsUS$1.95m4.97%
$ 21.8m
Robert Carpenter
Co-Founder & Chair Emeritus17.9yrsUS$84.74k1.78%
$ 7.8m
Brett Hall
Chief Scientific Officer6.1yrsUS$1.43m0.58%
$ 2.5m
Michael Bookman
Chief Legal Officer & Secretary4.4yrsUS$1.09m0.0075%
$ 33.2k
Mallory Morales
Principal Financial & Accounting Officer3.3yrsno data0.043%
$ 187.5k
Paula George
Director of Accounting & Operations and Assistant Corporate Controller4.3yrsno datano data
Leah Neufeld
Chief People Officer3.2yrsno data0.036%
$ 159.0k
Peter King
Head of Discovery & VPno datano datano data
Praveen Nair
Head of Translational Pharmacology & VP3.8yrsno datano data
Harold Brakewood
Chief Business Officer2.8yrsUS$1.57m0.0090%
$ 39.5k
Igor Matushansky
Chief Medical Officerless than a yearno datano data
Stephen Sebastian
Executive Director & Corporate Controller4.3yrsno datano data
4.3yrs
Average Tenure
52.5yo
Average Age

Experienced Management: IMRX's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Benjamin Zeskind
Co-Founder17.8yrsUS$1.95m4.97%
$ 21.8m
Robert Carpenter
Co-Founder & Chair Emeritus16.6yrsUS$84.74k1.78%
$ 7.8m
Laurie Keating
Independent Director4.8yrsUS$97.24k0.022%
$ 95.3k
Douglas Lauffenburger
Member of Scientific Advisory Boardno datano datano data
Thomas Schall
Chairman of the Board1.8yrsUS$204.84k0.082%
$ 360.1k
Peter Feinberg
Director4.9yrsUS$91.24k1.77%
$ 7.8m
Jordan Berlin
Member of Pancreatic Cancer Advisory Board1yrno datano data
Diana Hausman
Independent Director3.9yrsUS$92.74k0.0085%
$ 37.5k
Tanios Bekaii-Saab
Member of Pancreatic Cancer Advisory Boardno datano datano data
Vincent Chung
Member of Pancreatic Cancer Advisory Board1yrno datano data
Shubham Pant
Member of Pancreatic Cancer Advisory Board1yrno datano data
3.9yrs
Average Tenure
65yo
Average Age

Experienced Board: IMRX's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 23:52
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immuneering Corporation is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yevgeniya LivshitsChardan Capital Markets, LLC
Michael YeeJefferies LLC
Andrew BerensLeerink Partners LLC